| Ytd | 52.20% | |
| 1y | -62.55% |
| Open | 19.08 | Prev Close | 19.05 | Low | 18.91 | High | 20.08 | Mkt Cap | 1.66B |
| Vol | 1.15M | Avg Vol | 1.10M | EPS | -3.87 | P/E | -5.18 | Forward P/E | -5.94 |
| Beta | 1.04 | Short Ratio | 5.02 | Inst. Own | 79.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 18.86 | 200-d Avg | 15.78 | 1yr Est | 28.00 |
MLTX News
Leerink Partners analyst Thomas Smith maintains MoonLake (NASDAQ:MLTX) with a Outperform and rais
U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates
MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology compa
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera
MoonLake reported durable one-year Phase 3 hidradenitis suppurativa data for sonelokimab and plans a
SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth
Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradeni
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page
